We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 32.00 | 0.29% | 10,946.00 | 10,952.00 | 10,954.00 | 10,954.00 | 10,764.00 | 10,914.00 | 1,402,659 | 16:35:03 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 28.51 | 169.81B |
From Apr 2022 to Apr 2024
By Denny Jacob
International stocks trading in New York closed lower on Wednesday.
The S&P/BNY Mellon index of American depositary receipts slipped 1.1% to 137.43. The European index ticked down 0.8% to 128.28. The Asian index declined 1.6% to 167.97. The Latin American index retreated 1.2% to 179.63, while the emerging-markets index lost 1.9% to 283.78.
ArcelorMittal SA was among those whose ADRs traded actively.
The steel maker declined 8.5% after signing a memorandum of understanding with energy company RWE AG to work together to develop, build and operate offshore wind farms and hydrogen facilities in Germany.
Anglo-Swedish pharma giant AstraZeneca PLC rose 1.2% following an agreement with Biocartis Group NV aimed at the development and applicable pre-market notification or approval with the U.S. Food and Drug Administration of a companion diagnostic test on Biocartis' Idylla platform for use with AstraZeneca's Tagrisso.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
June 22, 2022 16:23 ET (20:23 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
